Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FICOXPEA is a phytotherapeutic oral supplement developed by Kura srl that combines phycocyanin, palmitoylethanolamide (PEA), and selenium (as L-selenomethionine). Phycocyanin, a pigment-protein complex extracted from *Spirulina platensis*, acts as a selective inhibitor of cyclooxygenase-2 (COX-2) and a potent scavenger of reactive oxygen species (ROS). Palmitoylethanolamide is an endogenous fatty acid amide that exerts anti-inflammatory and analgesic effects by modulating mast cell activation and activating the peroxisome proliferator-activated receptor alpha (PPAR-alpha). Selenium is included as L-selenomethionine to support antioxidant defenses as a cofactor for glutathione peroxidase. The combination is primarily used to manage inflammatory and painful conditions of the prostate and pelvic area, such as Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) and benign prostatic hyperplasia (BPH), and is also being explored for menstrual migraine prophylaxis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phycocyanin + palmitoylethanolamide + selenium.